10x Genomics reported third quarter 2025 revenue of $149.0 million, a 2% decrease from the same period in 2024, mainly due to lower instrument revenue. Excluding a one-time license and royalty revenue of $27.3 million in the previous quarter, third quarter revenue increased 2% sequentially. The company posted an operating loss of $32.2 million, compared to $41.5 million a year earlier, and a net loss of $27.5 million, down from $35.8 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $482.1 million at the end of the quarter, up $35 million from the previous quarter. Notable business developments included the launch of the next-generation Chromium Flex for scalable single cell analysis and Xenium Protein, a spatial multiomic workflow for simultaneous RNA and protein detection. For the fourth quarter of 2025, 10x Genomics expects revenue between $154 million and $158 million, representing a 6% decline from the prior year period and 5% sequential growth at the midpoint.